Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

NCT00945763 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 230

Last updated 2011-12-02

No results posted yet for this study

Summary

To evaluate the safety and efficacy of single IV doses of N1539 after dental impaction surgery.

Conditions

  • Dental Pain

Interventions

DRUG

N1539

30 mg

DRUG

placebo

tablets

DRUG

N1539

15 mg

DRUG

N1539

60 mg

DRUG

Motrin

400 mg

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven Christensen, DDS · Jean Brown Research, Salt Lake City, UT 84124

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00945763 on ClinicalTrials.gov